RBC Capital Reiterates Outperform on IDEAYA Biosciences, Maintains $45 Price Target
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
RBC Capital analyst Leonid Timashev reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $45 price target.
RBC Capital analyst Leonid Timashev reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $45 price target.
